Product Images Cyclobenzaprine Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Cyclobenzaprine Hydrochloride NDC 68071-3154 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

68071 3154 3

68071 3154 3

The given text seems to contain some product details. However, it is unclear due to several gibberish characters. The product appears to be Cyclobenzaprine HCl 10mg, and it comes in a quantity of three (#3). The remaining text includes information about the manufacturer, storage conditions, dosage instructions, and contact details for adverse reactions reporting. The lot number, GTIN, serial number, and expiration date are also mentioned.*

Image - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01

Image - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01

IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02

IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02

This is a comparison of the side effects of two doses (5mg and 10mg) of Cyclobenzaprine HCI tablets versus a placebo. The commonly reported side effects of Cyclobenzaprine HCI tablets are drowsiness, dry mouth, fatigue and headache. The table shows the percentage of patients who experienced these side effects in each group. For example, in the group taking the 5mg dose, 29% of patients experienced drowsiness, 21% experienced dry mouth, 6% experienced fatigue and 5% experienced headaches. The placebo group had a much lower incidence of side effects.*

IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03

IMAGE - 7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03

This text appears to provide information on clinical studies and a surveillance program involving Cyclobenzaprine HClI tablets with a dosage of 10 mg. The text outlines the percentages of three potential side effects, including drowsiness at 39%, dry mouth at 2%, and dizziness at 1%. The surveillance program also highlights additional side effects, with an incidence rate of 16% for an unknown side effect, 7% for dry mouth, and 3% for drowsiness.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.